The company plans to launch two new studies aimed at evaluating the experimental treatment across a wider patient population. This strategic shift follows promising Phase 2 data, which indicated that over half of the participants experienced measurable tumor shrinkage, with the therapeutic response proving durable over time.
In section Market Quotes
Nuvation Bio Shares Rally on Expanded Safusidenib Clinical Trials
Following a 28% decline since January, Nuvation Bio shares climbed 11% to $6.41 after the company announced a significant expansion of its clinical program for safusidenib. The oncology firm is now targeting a broader spectrum of IDH1-mutant glioma, a complex form of brain cancer, to test the drug's efficacy.
Chief Executive David Hung described the move as a pivotal progression for the drug, shifting the focus toward capturing a more diverse landscape of glioma cases. While the recent market surge offers a reprieve for investors, the company remains focused on translating these clinical milestones into long-term medical viability for patients battling IDH1-mutant tumors.
Comments (0)
No comments yet. Be the first!